EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of PBP3 insertions and β-lactamase-encoding genes on the susceptibility of Escherichia coli isolates belonging to high-risk clones against aztreonam-avibactam and comparator agents

Mariana Castanheira iD, John H Kimbrough iD, Maura Karr iD, Helio S Sader iD

Antimicrobial Agents and Chemotherapy · 07.10.2026 · 70 (10)

DOI: 10.1128/aac.00129-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 07.10.2026. Verfasst von Mariana Castanheira und 3 weiteren Autor:innen. Beteiligte Einrichtung: Element Materials Technology (JMI Laboratories), North Liberty, Iowa, USA. Hauptthemen laut MEDLINE: Aztreonam, Escherichia coli, beta-Lactamases, Anti-Bacterial Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer's Centers for Therapeutic Innovation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We evaluated the presence and phenotypic impact of PBP3 insertions YRIN ( n = 44) and YRIK ( n = 18) among 124 Escherichia coli isolates belonging to high-risk lineages selected from 1,471 isolates displaying resistance to β-lactams. PBP3 insertions were detected among 62 isolates. YRIN insertions were detected among isolates belonging to ST167 ( n = 23), ST361 ( n = 7), ST410 ( n = 10), ST617 ( n = 1), and ST648 ( n = 3), while YRIK insertions were observed in ST405 ( n = 9), ST410 ( n = 5), and ST617 ( n = 4). Aztreonam-avibactam inhibited 90.3% of all isolates from high-risk clones and 80.6% of the isolates harboring PBP3 insertions when applying the EUCAST breakpoints. Aztreonam-avibactam inhibited 66.7% of the YRIK-harboring isolates (MIC 50/90 , 2/16 mg/L) and 86.4% of the ones harboring YRIN insertions (MIC 50/90 , 1/8 mg/L); however, the susceptibilities to other β-lactams were lower among YRIN isolates (25.6%–60.5%) compared to YRIK (55.6%–88.9%). Overall, ST617 was more resistant to all agents when compared to other STs, regardless of PBP3 insertions or the presence of other examined resistance mechanisms. Acquired β-lactamase genes and OmpC deleterious alterations were present in all isolates. CMY-42, CMY-141, and CMY-145 that have been associated with elevated aztreonam-avibactam MICs were detected among 13 isolates, and 4 (30.8%) were susceptible to this combination. All isolates harboring bla NDM-5 ( n = 37) possessed PBP3 insertions. Aztreonam-avibactam inhibited 83.8% of these isolates. Resistance to aztreonam-avibactam is multifactorial, and singular resistance mechanisms are unable to elevate MIC values to resistant categories. Additionally, lineage-specific contributions to resistance play an important role in the overall development of β-lactam resistance, although these mechanisms appear to function outside the known repertoire of resistance-conferring mutations and warrant further study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AztreonamEscherichia colibeta-LactamasesAnti-Bacterial AgentsAzabicyclo CompoundsPenicillin-Binding ProteinsMicrobial Sensitivity TestsEscherichia coli ProteinsDrug Resistance, Multiple, BacterialDrug Combinations

Stichwörter der Autor:innen

PBP3 insertionsβ-lactam resistanceβ-lactam/β-lactamase inhibitor combinationsβ-lactamases

Substanzen

Aztreonambeta-LactamasesAnti-Bacterial AgentsAzabicyclo CompoundsavibactamPenicillin-Binding ProteinsEscherichia coli Proteinsaztreonam, avibactam drug combinationDrug Combinations

Autor:innen und Institutionen

  • Element Materials Technology (JMI Laboratories), North Liberty, Iowa, USA.

ORCID-Profile: Mariana Castanheira, John H Kimbrough, Maura Karr, Helio S Sader

Förderung

  • Pfizer's Centers for Therapeutic Innovation

Zitieren

APA

Castanheira, M., Kimbrough, J. H., Karr, M., & Sader, H. S. (2026). Impact of PBP3 insertions and β-lactamase-encoding genes on the susceptibility of Escherichia coli isolates belonging to high-risk clones against aztreonam-avibactam and comparator agents. Antimicrobial Agents and Chemotherapy, 70(10). https://doi.org/10.1128/aac.00129-26

Vancouver

Castanheira M, Kimbrough JH, Karr M, Sader HS. Impact of PBP3 insertions and β-lactamase-encoding genes on the susceptibility of Escherichia coli isolates belonging to high-risk clones against aztreonam-avibactam and comparator agents. Antimicrobial Agents and Chemotherapy. 2026;70(10). doi:10.1128/aac.00129-26

BibTeX
@article{Castanheira2026,
  author = {Castanheira, Mariana and Kimbrough, John H and Karr, Maura and Sader, Helio S},
  title = {Impact of PBP3 insertions and β-lactamase-encoding genes on the susceptibility of Escherichia coli isolates belonging to high-risk clones against aztreonam-avibactam and comparator agents},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  volume = {70},
  number = {10},
  doi = {10.1128/aac.00129-26}
}
Kostenlos starten →